Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer

[1]  Delin Yang,et al.  Prognostic significance of SNCA and its methylation in bladder cancer , 2022, BMC Cancer.

[2]  Luyao Wang,et al.  Comprehensive Analysis of DNA 5-Methylcytosine and N6-Adenine Methylation by Nanopore Sequencing in Hepatocellular Carcinoma , 2022, Frontiers in Cell and Developmental Biology.

[3]  Chujun Li,et al.  Next frontier in tumor immunotherapy: macrophage-mediated immune evasion , 2021, Biomarker research.

[4]  R. DuBois,et al.  Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. , 2021, Gastroenterology.

[5]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[6]  Dongqiang Zeng,et al.  IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures , 2020, bioRxiv.

[7]  G. Colombo,et al.  Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity , 2020, Biology.

[8]  D. Schlaepfer,et al.  FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer , 2020, EMBO molecular medicine.

[9]  X. Sang,et al.  Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma , 2020, Cancer medicine.

[10]  Weiwei Qi,et al.  Inhibiting Forkhead box K1 induces autophagy to reverse epithelial-mesenchymal transition and metastasis in gastric cancer by regulating Myc-associated zinc finger protein in an acidic microenvironment , 2020, Aging.

[11]  Hao Wang,et al.  Stromal-Immune Score-Based Gene Signature: A Prognosis Stratification Tool in Gastric Cancer , 2019, Front. Oncol..

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  T. Lei,et al.  Modification of α2,6‐sialylation mediates the invasiveness and tumorigenicity of non‐small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway , 2018, International journal of cancer.

[14]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[15]  Mingjian Long,et al.  Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas , 2018, bioRxiv.

[16]  K. D. Sørensen,et al.  Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies , 2018, Molecular oncology.

[17]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[18]  S. Donnini,et al.  Linking of mPGES-1 and iNOS activates stem-like phenotype in EGFR-driven epithelial tumor cells. , 2017, Nitric oxide : biology and chemistry.

[19]  T. Sano.  Gastric cancer: Asia and the world , 2017, Gastric Cancer.

[20]  K. Zen,et al.  Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells , 2016, Proceedings of the National Academy of Sciences.

[21]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[22]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[23]  R. Santi,et al.  mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity , 2015, Endocrine-related cancer.

[24]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[25]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[26]  S. Yamada,et al.  Epithelial‐to‐mesenchymal transition predicts prognosis in clinical gastric cancer , 2014, Journal of surgical oncology.

[27]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[28]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[29]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[30]  Chandran Nair.  Asia and the World , 2012 .

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  G. Melillo,et al.  Inhibition of Hypoxia Inducible Factor-1α by Dihydroxyphenylethanol, a Product from Olive Oil, Blocks Microsomal Prostaglandin-E Synthase-1/Vascular Endothelial Growth Factor Expression and Reduces Tumor Angiogenesis , 2010, Clinical Cancer Research.

[33]  E. Neilson,et al.  Biomarkers for epithelial-mesenchymal transitions. , 2009, The Journal of clinical investigation.

[34]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[35]  H. Harizi,et al.  Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. , 2008, Trends in molecular medicine.

[36]  R. Klein,et al.  Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor‐mediated cAMP pathway , 2007, Molecular carcinogenesis.

[37]  William L. Smith,et al.  Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*♦ , 2007, Journal of Biological Chemistry.

[38]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[39]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[40]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[41]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[42]  Y. Sugimoto,et al.  Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. , 2001, Biochemical pharmacology.

[43]  T. Kawaguchi,et al.  Expression of cyclooxygenase‐2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation , 1999, Hepatology.

[44]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[45]  W A Kuperman,et al.  Focalization: environmental focusing and source localization. , 1991, The Journal of the Acoustical Society of America.

[46]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.

[47]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[49]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.